Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Daniel Lettiere"'
Autor:
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao, Maureen Cruz
Publikováno v:
PDA Journal of Pharmaceutical Science and Technology. 76:369-383
The threshold of toxicological concern (TTC), i.e., the dose of a compound lacking sufficient experimental toxicity data that is unlikely to result in an adverse health effect in humans, is important for evaluating extractables and leachables (ELs) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e5cd88a83a00b14c556d652d030bc6a
https://doi.org/10.5731/pdajpst.2021.012693
https://doi.org/10.5731/pdajpst.2021.012693
Autor:
David A. Griffith, David J. Edmonds, Jean-Philippe Fortin, Amit S. Kalgutkar, J. Brent Kuzmiski, Paula M. Loria, Aditi R. Saxena, Scott W. Bagley, Clare Buckeridge, John M. Curto, David R. Derksen, João M. Dias, Matthew C. Griffor, Seungil Han, V. Margaret Jackson, Margaret S. Landis, Daniel Lettiere, Chris Limberakis, Yuhang Liu, Alan M. Mathiowetz, Jayesh C. Patel, David W. Piotrowski, David A. Price, Roger B. Ruggeri, David A. Tess
Publikováno v:
Journal of medicinal chemistry. 65(12)
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff991134db369ff3aa7ceaecc2f6263e
https://pubmed.ncbi.nlm.nih.gov/35647711
https://pubmed.ncbi.nlm.nih.gov/35647711